Tags |
|
|
Links |
|
|
Top Adding - Patent Citation Data for Competitive Intelligence
Patents are most comprehensive and well documented technological and competitive information source. The most important is that i
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
t freely accessible through internet. Studies of technological change constitute a field of growing importance and sophistication
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
. Just as it does in scientific papers, citation plays an important role in the patents field. The inventor uses it to indicate t
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
e stage of technology previously reached, upon which his invention improves. However, a patent examiner may find patents that co
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
uld counter-indicate granting of a patent and 'oppose' the application. These citations are usually included in databases under ‘
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
eferenced Patents ‘or ‘Referenced Literature’.
Citation analysis is used to evaluate and weighs the possible opportunities
Citation analysis is used to evaluate and weighs the possible opportunities
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
and risks of engaging in particular technologies. Careful analysis and understanding helps decision makers to establish offensive
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
licensing strategy to add on new revenue. It can provide information on who are involved in your technologies at a glance. Citati
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
on analysis data is most important in revealing new licensing opportunities, identification of key competitors and technological
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
evelopment and trends.
In case companies do not recognize that internal development efforts alone hardly bring business adv
In case companies do not recognize that internal development efforts alone hardly bring business adv
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
antage in their business environments where innovators abound, they might be exposed in risks and trapped in the future. By esta
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
blishing effective licensing-in strategy to find external business partner for collaboration, companies can be free from this haz
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
rds and reap profits in an era of rampant technology change.
The Citation analysis enables companies to establish the stra
The Citation analysis enables companies to establish the stra
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
tegies by identifying desirable technology for faster time to market without potential risks.
Citation searching and analys
Citation searching and analys
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
s provides a lot of information and can be used to:
Enhance a prior art or patentability search - e.g., assist in retri
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
eving the "unique" document supporting a validity search
Analyze major competitors
Monitor a patent portfolio for possi
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
le infringement
Identify especially important intellectual property based on number of citations
Assist in legal challe
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
nges
Licensing opportunities
Acquisition possibility
Competitors working in similar area of research
Possible
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
infringement
Identification of important and potent technology (most cited)
Identification of landmark publication tha
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
t establishes important prior art, or establishes limits of "obviousness" or "best mode" in prosecuting a patent application.
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.topadding.org.ua/article/130720/topadding-Patent-Citation-Data-for-Competitive-Intelligence.html">Patent Citation Data for Competitive Intelligence</a>
BB link (for phorums):
[url=http://www.topadding.org.ua/article/130720/topadding-Patent-Citation-Data-for-Competitive-Intelligence.html]Patent Citation Data for Competitive Intelligence[/url]
Related Articles:
Tips from a San Diego Video Production: Pre-interview Your Subjects
Bookmark it:
|